Klein John, Jepsen Amelia, Patterson Amy, Reich Richard R, Mason Tina M
H. Lee Moffitt Cancer Center and Research Institute.
Central Florida SurgiCenter.
Clin J Oncol Nurs. 2018 Apr 1;22(2):199-202. doi: 10.1188/18.CJON.199-202.
Patients undergoing blood and marrow transplantation (BMT) use a central venous catheter (CVC); heparin is often employed to maintain patency but may increase the risk of complications. Research has not provided conclusive differences in efficacy and safety regarding heparin flushing versus normal saline flushing in CVC maintenance. Minimal research is specific to this patient population.
This study aimed to determine if differences exist in CVC patency, tissue plasminogen activator usage, and the incidence of central line-associated bloodstream infections when flushing with normal saline only versus heparin and normal saline among patients undergoing BMT.
A convenience sample of 30 patients undergoing allogeneic or autologous transplantation with a new non-port/non-peripherally inserted CVC were evaluated.
Elimination of routine heparin use could positively affect outcomes in this patient population.
接受血液和骨髓移植(BMT)的患者使用中心静脉导管(CVC);肝素常用于维持导管通畅,但可能会增加并发症风险。关于在CVC维护中肝素冲洗与生理盐水冲洗在疗效和安全性方面的差异,研究尚未得出确凿结论。针对该患者群体的具体研究极少。
本研究旨在确定在接受BMT的患者中,仅用生理盐水冲洗与用肝素和生理盐水冲洗相比,在CVC通畅性、组织纤溶酶原激活剂的使用以及中心静脉导管相关血流感染的发生率方面是否存在差异。
对30例接受同种异体或自体移植且使用新的非端口/非外周插入式CVC的患者进行便利抽样评估。
在该患者群体中,取消常规肝素使用可能对结果产生积极影响。